Dr Sarah Hudson studied chemistry at Trinity College Dublin, obtained a PhD from the University of Limerick in immobilised enzyme biocatalysis and did two postdoctoral positions in MIT, Boston and WIT, Waterford in drug delivery and pharmaceutics. Sarah is now a senior lecturer in chemistry in the Department of Chemical, a principal investigator in the SFI Research Centre for Pharmaceuticals (SSPC) and a researcher in the Bernal Institute in the University of Limerick. Since graduating with her PhD in 2006, Sarah has secured over €7m in funding from EU, Exchequer and industrial funding with recent projects including in a Disruptive Technologies Innovation Award (2019) and SFI New Frontiers funding (2020) which focus on the development of enzymes and peptides into medicines as well as leading a Marie Curie European Industrial Doctorate with TU Dortmond and Janssen in Belgium on the development of long acting injectable medicines (2019). These projects are based in the Biologicals Process Infrastructure Testbed, BioPoint and the SSPC. BioPoint was created and officially opened in 2018 from a Science Foundation Ireland (SFI) Infrastructure Award which Sarah also led. Sarah engages and supports industrial activities through close collaborations with many pharmaceutical companies in Ireland and Europe. She recently had a patent awarded on the development of nanomedicines and is conducting a feasibility study with EI currently to look at commercialisation of the invention. Sarah has graduated 9 PhD and 2 Research Masters students, while her current team includes 21 researchers (7 Post-Doctoral Researchers, 12 PhD candidates and 2 research assistants).